-CNBC’s “Fast Money: Halftime Report”
Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update
The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data.